Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Clarity in Trials, Confidence in Decisions
Clarity in Trials, Confidence in Decisions
Deucravacitinib (SOTYKTU) — Drug Profile | TrialistMD TRIALISTMD.COM DRUG PROFILE TYK2 Inhibitor · Dermatology · Plaque Psoriasis Deucravacitinib SOTYKTUâ„¢ · Bristol-Myers Squibb Company The world’s first tyrosine kinase 2 (TYK2) inhibitor approved for any indication. Deucravacitinib binds selectively to the…
Ritlecitinib (LITFULO) — Drug Profile | TrialistMD TRIALISTMD.COM DRUG PROFILE JAK3 / TEC Kinase Inhibitor · Dermatology · Alopecia Areata Ritlecitinib LITFULO™ · Pfizer Labs, Division of Pfizer Inc. A first-in-class irreversible, covalent inhibitor of JAK3 and the TEC kinase…
Sofpironium (Sofdra) — Drug Profile | TrialistMD TRIALISTMD · Drug Intelligence Platform NDA 217347 — 2024 Anticholinergic · Dermatology · Primary Axillary Hyperhidrosis Sofpironium Sofdra™ · Botanix Pharmaceuticals Sofpironium bromide is a new molecular entity and small molecule quaternary ammonium…
LetibotulinumtoxinA (LETYBO) — Drug Profile | TrialistMD TRIALISTMD BLA 761225 Acetylcholine release inhibitor · Neuromuscular blocking agent LetibotulinumtoxinA LETYBO (letibotulinumtoxinA-wlbg) An acetylcholine release inhibitor and neuromuscular blocking agent (botulinum toxin type A; 900 kDa) indicated for the temporary improvement in…
DaxibotulinumtoxinA-lanm (DAXXIFY) — Drug Profile | TrialistMD TRIALISTMD.COM DRUG PROFILE Botulinum Neurotoxin Type A · Neuromuscular Blocking Agent · Dermatology / Aesthetics DaxibotulinumtoxinA-lanm DAXXIFY™ · Revance Therapeutics, Inc. A 150 kDa botulinum toxin type A without accessory proteins, formulated with…
Berdazimer (ZELSUVMI) — Drug Profile | TrialistMD TRIALISTMD.COM DRUG PROFILE Nitric Oxide Releasing Agent · Topical Small Molecule · Dermatology / Virology Berdazimer ZELSUVMI™ · EPIH SPV, LLC (developed by Novan, Inc.) A first-in-class topical nitric oxide (NO) releasing agent…
Abrocitinib (CIBINQO) — Drug Profile | TrialistMD TRIALISTMD.COM DRUG PROFILE JAK1 Inhibitor (Selective) · Small Molecule · Dermatology Abrocitinib CIBINQO™ · Pfizer Labs, Division of Pfizer Inc. A selective, reversible JAK1 inhibitor that blocks the ATP binding site at JAK1…
spesolimab (SPEVIGO) — Drug Profile | TrialistMD TRIALISTMD.COM DRUG PROFILE IL-36R Antagonist · Humanized mIgG1 · Dermatology Spesolimab SPEVIGO® · Boehringer Ingelheim Pharmaceuticals, Inc. The first and only FDA-approved interleukin-36 receptor (IL-36R) antagonist — and the first therapy specifically approved…
Delgocitinib (ANZUPGO) — Drug Profile | TrialistMD TRIALISTMD.COM DRUG PROFILE JAK Inhibitor (Pan-JAK) · Small Molecule · Dermatology Delgocitinib ANZUPGO® · 2% cream (20 mg/g) First-in-class topical pan-JAK inhibitor (JAK1/2/3/TYK2) approved for moderate to severe chronic hand eczema (CHE) in…
Bimekizumab (BIMZELX) — Drug Profile | TrialistMD TRIALISTMD.COM DRUG PROFILE IL-17A & IL-17F Inhibitor · IgG1 Monoclonal Antibody · Dermatology Bimekizumab BIMZELX® · UCB, Inc. A humanized IgG1 monoclonal antibody that selectively inhibits both IL-17A and IL-17F — the first…